Evogene Ltd. (EVGN)

Market Cap	6.20M -45.1%
Revenue (ttm)	1.66M -73.1%
Net Income	-9.07M
EPS	-0.90
Shares Out	13.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,915
Open	0.3750
Previous Close	0.3795
Day's Range	0.3750 - 0.3800
52-Week Range	0.3521 - 1.4900
Beta	0.72
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 52
• Stock Exchange: Nasdaq
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 15, 2026

Data Sources Report a data error